Opsens Inc. announced 510(k) clearance from the U.S. Food and Drug Administration to market its OptoWire III, a coronary pressure guidewire for physiological measurements such as Fractional Flow Reserve and Diastolic Pressure Ratio ("dPR"). The OptoWire III is the latest version of OptoWire. The OptoWire family of products are used to diagnose and guide the treatment of patients with coronary heart disease. Securing 510(k) is an important step in Opsens' plan to grow revenues in the U.S., as the Company is constantly improving its products to increase penetration in the U.S. and other targeted markets. In addition to the United States and Canada, Opsens has also filed applications for approval in Japan, and Europe.